Radical multimodality therapy for malignant pleural mesothelioma

Abdel‐Rahman, Omar; Elsayed, Zeinab; Mohamed, Hadeer; Eltobgy, Mostafa

doi:10.1002/14651858.cd012605.pub2

Cited by 24 publications

(29 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some germline mutations were also shown to predispose to mesothelioma (most commonly germline BAP1 mutations) which was associated with familial cases of mesothelioma . Other risk factors which were associated with mesothelioma development include exposure to irradiation, simian virus 40 (SV40), and erionite . It has to be stressed, however, that assessing and quantifying these factors are challenging and the literature is scarce.…”

Section: Discussionmentioning

confidence: 99%

Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994‐2013)

Abdel‐Rahman

2018

Clinical Respiratory J

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994‐2013)

Abdel‐Rahman

2018

Clinical Respiratory J

Self Cite

View full text Add to dashboard Cite

show abstract

“…So, the possible reason may be that the topics of the Chinese Cancer-CSR studies are not attractive and innovative enough. Egypt and Austria were the first time to publish the reviews in Cancer-CSR during the latest ten years, which focused more on the chemotherapy and multimodality therapy in cancer field (36,37) .…”

Section: General Informationmentioning

confidence: 99%

Trends analysis of cancer topic of Cochrane systematic reviews: a bibliometric analysis

Yang

Gao

Cai

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose: To analyze the scientific outputs of the cancer topic of Cochrane systematic reviews (Cancer-CSR) in order to have a comprehensive understanding and lay the foundation for the following research. Patients and methods: Cochrane Database of Systematic Review and Web of Science Core Collection were retrieved limited from Jan. 1, 2009 to Dec. 12, 2018. CiteSpace IV and Excel 2018 were applied to analyze and visualize the literature information. Results: Ultimately, 607 Cancer-CSR were retrieved, 32 countries, 179 institutions and 260 authors involved. The number of publications in Cancer-CSR has been increasing over the past decades (25(2009)-77(2018)). UK, USA, Canada, Australia, and Germany worked closely with other countries, especially the UK (n=361) has taken the lead in this field. The top 10 contributive institutions, which were almost came from developed countries, collaborated closely with other institutions. Cochrane Database Syst Rev, C Hdb Sys and J Clin Oncol were the top three journals with the highest co-citation. The top three co-cited references were the two different version of Cochrane handbook for systematic reviews and the guidelines of Review Manager. The biggest cluster of keywords “cytoreductive surgery (CRS)” and the latest clusters “visual inspection” and “non-steroidal anti-inflammatory drug” were the most promising hotspots. Conclusions: Cancer-CSR has been increasing. Most of the reviews were came from the developed countries as well as the institutes in these countries. The knowledge base of was the methodology studies of systematic review, epidemiological data of cancer, and the reporting guideline of systematic reviews. The adjuvant therapy combined CRS, the screening of skin cancer and the management of cancer-related pain were the hotspots. Reasons that influence the author's preference for Cancer-CSR also deserve further investigation.

show abstract

“…Depending on patient-and disease-related factors, treatment options may include surgery, chemotherapy, and radiation therapy (RT) and should be determined through a multidisciplinary management approach in experienced cancer centers. Despite advancements in treatment modalities, the prognosis of malignant mesothelioma remains poor with a median overall survival (OS) of 12--22 months [13,[17][18][19]. Given the constantly evolving treatment paradigm, we herein evaluate the published data on therapeutic options for MPM and propose a functional treatment algorithm.…”

Section: Introductionmentioning

confidence: 99%

Current Treatment Strategies in Malignant Pleural Mesothelioma with a Treatment Algorithm

Sayan

Eren

Gupta

et al. 2019

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare disease with a poor prognosis. The main therapeutic options for MPM include surgery, chemotherapy, and radiation therapy (RT). Although multimodality therapy has been reported to improve survival, not every medically operable patient is able to undergo all recommended therapy. With improvements in surgical techniques and systemic therapies, as well as advancements in RT, there has been a potential new paradigm in the management of this disease. In this review, we discuss the current literature on MPM management and propose a functional treatment algorithm.

show abstract

Radical multimodality therapy for malignant pleural mesothelioma

Cited by 24 publications

References 59 publications

Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994‐2013)

Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994‐2013)

Trends analysis of cancer topic of Cochrane systematic reviews: a bibliometric analysis

Current Treatment Strategies in Malignant Pleural Mesothelioma with a Treatment Algorithm

Contact Info

Product

Resources

About